Fundraise

Commit Biologics closes €54M seed to take immune engagers to the clinic

What's the deal? Copenhagen-based Commit Biologics has closed a $60 million (€54 million) seed round to push its complement-powered immune engagers toward the clinic. Ackermans & van HaarenDealroom has a profile for this one. Try Dealroom → led, with new investors AbbVie Ventures and M VenturesDealroom has a profile for this one. Try Dealroom → joining existing backers Bioqube VenturesDealroom has a profile for this one. Try Dealroom →, Korys, and Novo HoldingsDealroom has a profile for this one. Try Dealroom →.

What's the endgame? Commit, a spin-out from Aarhus University, builds bispecific antibodies that recruit the complement protein C1q to selectively destroy diseased cells — a mechanism that works independently of T cells. The money will fund IND-enabling work and an IND filing for lead candidate COM002, advance a second program, and expand its BiCE platform.

Why now? The raise follows two milestones: proof-of-concept data in non-human primates and the nomination of COM002 as its first development candidate this month. COM002 targets both cancer and autoimmune disease.

Why it stands out: At €54 million, this is among the largest seed rounds for a Danish health company on record, ranking in the top 1% of 159 comparable deals. It is unusually big for a company still preparing its first candidate for the clinic.

"Complement is among the immune system's most potent effector mechanisms yet remains largely untapped in drug development," said Charlotte Kremers, principal at M Ventures. Three investors — Michael Rosenzweig of AbbVie Ventures, Kremers, and Lenny Van Steenhuyse of Ackermans & van Haaren — join Commit's board.

What could go wrong? Commit's evidence remains preclinical. The round finances a clinical transition, not clinical validation; the platform has yet to be tested in humans.

The signal: Investor appetite for immune-engager and cell-depletion developers is building, with recent rounds for T-Therapeutics ($133 million) and Dren Bio ($350 million). Commit's raise is notable less for data than for the size of the bet placed on an unproven approach at an early stage.

Read more: pr.southjordanjournal.com

Image credit: Commit Biologics

More top stories